Larry Robbins Portfolio
Invests via Glenview Capital Management | Managed by Larry Robbins
Invests via Glenview Capital Management
Managed by Larry Robbins
Automatically Tracked
Runs a value-oriented long/short equity shop with a concentration in healthcare and consumer franchises, pursuing concentrated public-equity positions and occasional activist engagement to influence corporate strategy and board composition. The investment approach blends fundamental research with industry specialization to identify durable cash-flow compounders and restructuring candidates across the U.S. market. Larry Robbins founded and serves as CEO of his flagship firm, which manages institutional capital for pensions, endowments and family offices while retaining a high-conviction portfolio construction style and a bias toward deep sector expertise that informs both stock selection and risk management.
Runs a value-oriented long/short equity shop with a concentration in healthcare and consumer franchises, pursuing concentrated public-equity positions and occasional activist engagement to influence corporate strategy and board composition. The investment approach blends fundamental research with industry specialization to identify durable cash-flow compounders and restructuring candidates across the U.S. market. Larry Robbins founded and serves as CEO of his flagship firm, which manages institutional capital for pensions, endowments and family offices while retaining a high-conviction portfolio construction style and a bias toward deep sector expertise that informs both stock selection and risk management.
Investment Philosophy & Strategy
Value-driven long/short equity investor with concentrated, high-conviction portfolios focused on healthcare and consumer franchises. Emphasizes deep fundamental research and sector specialization to uncover durable cash-flow compounders, turnaround and restructuring opportunities, and selective activist initiatives to reshape corporate strategy and governance. Capital allocation favors concentrated positions with active risk controls, multi-year time horizons, and opportunistic use of leverage and hedges to protect downside while maximizing asymmetric upside for institutional mandates.
Value-driven long/short equity investor with concentrated, high-conviction portfolios focused on healthcare and consumer franchises. Emphasizes deep fundamental research and sector specialization to uncover durable cash-flow compounders, turnaround and restructuring opportunities, and selective activist initiatives to reshape corporate strategy and governance. Capital allocation favors concentrated positions with active risk controls, multi-year time horizons, and opportunistic use of leverage and hedges to protect downside while maximizing asymmetric upside for institutional mandates.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
85.57%
Gain +0.37%
Monthly
1%
Yearly
12.69%
Drawdown
20.83%
$5.4B
Equity
Holdings
$5.4B
Investment
$4.3B
$16.57B
Profit +$23.06M
Realized
$15.47B
Unrealized
$1.1B
Dividends
$1.6B
Goals
Avg. 95% completed goals
Yearly
Gain > 10% 2026
Yearly
Loss < 18% 2026
Yearly
Loss < $150M 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
0.37%
Profit
$23.06M
Win %
69%
This Week
Compared To Last Week
Gain
0.51%
Profit
$27.24M
Win %
69%
This Month
Compared to last month
Gain
3.43%
Profit
$179.19M
Win %
69%
This Year
Compared to last year
Gain
7.96%
Profit
$398.1M
Win %
64%
AMD Advanced Micro Devices, Inc.
+6.49%
+$9.36M 
GENI Genius Sports Ltd.
+5.94%
+$6.34M 
CVS CVS Health Corporation
+2.29%
+$10.52M 
CNC Centene Corporation
+2.18%
+$2.72M 
BKR Baker Hughes Company
+2.16%
+$676,121.03 
MCHP Microchip Technology Incorporated
+1.89%
+$390,398.19 
CAH Cardinal Health Inc.
+1.71%
+$71,170.92 
CI The Cigna Group
+1.64%
+$1.88M 
MKSI MKS Instruments Inc.
+1.45%
+$437,482.08 
EYE National Vision Holdings Inc.
+1.31%
+$775,273.85 
VTRS Viatris Inc.
+1.28%
+$2.02M 
HUM Humana Inc.
+1.1%
+$1.08M 
TEVA Teva Pharmaceutical Industries Ltd. ADR
+0.69%
+$1.27M 
STM STMicroelectronics N.V.
+0.67%
+$201,621.6 
ELV Elevance Health, Inc.
+0.53%
+$139,191.91 
BLCO Bausch + Lomb Corporation
+0.41%
+$134,268.44 
TECH Bio-Techne Corporation
+0.32%
+$13,414.52 
THC Tenet Healthcare Corporation
+0.32%
+$1.9M 
BSX Boston Scientific Corporation
+0.27%
+$15,833.44 
UBER Uber Technologies, Inc.
+0.06%
+$80,711.91 
AMAT Applied Materials, Inc.
-5.13%
-$1.79M 
LLY Eli Lilly and Company
-2.35%
-$1.64M 
GPN Global Payments Inc.
-1.88%
-$15.85M 
ONTO Onto Innovation Inc.
-1.81%
-$1.26M 
DOCN DigitalOcean Holdings Inc.
-1.78%
-$200,156.32 
FUN Six Flags Entertainment Corporation
-1.74%
-$585,168.09 
CSCO Cisco Systems, Inc.
-1.57%
-$735,730.96 
TMO Thermo Fisher Scientific Inc.
-1.32%
-$4.93M 
AMZN Amazon.com Inc
-0.93%
-$3.14M 
META Meta Platforms Inc Class A
-0.85%
-$1.81M 
UAL United Airlines Holdings, Inc.
-0.81%
-$504,630.72 
DHR Danaher Corporation
-0.71%
-$1.65M 
ABBV AbbVie Inc.
-0.55%
-$204,012.3 
ESI Element Solutions Inc.
-0.54%
-$208,859.9 
NVS Novartis AG Sponsored ADR
-0.53%
-$70,396.29 
AZN AstraZeneca PLC American Depositary Shares
-0.5%
-$143,737.62 
A Agilent Technologies Inc.
-0.49%
-$1.45M 
BRKR Bruker Corporation
-0.4%
-$57,998.87 
PRMB Primo Brands Corp. Common Stock
-0.28%
-$28,347.97 
XYZ Block, Inc.
-0.27%
-$263,345.33 
BFLY Butterfly Network, Inc.
-0.23%
-$286,701.1 
DKS Dick's Sporting Goods, Inc.
-0.14%
-$116,305.42 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 5080 | Longs Won 2796/5080 55% | Profit Factor 2.25 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $22.03M |
| Average Win $10.69M | Best Trade (Mar 31) $588.06M | Sharpe Ratio -40.61 |
| Average Loss -$5.83M | Worst Trade (Mar 31) -$162.06M | Z-Score -24.74 (100%) |
| Commissions $0 | Avg. Trade Length 1y 1m 3w 5d | Expectancy $3.26M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.05% |
| Consecutive Losing Trades | 927 | 834 | 741 | 649 | 556 | 463 | 371 | 278 | 185 | 93 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies Inc. | 1.97M | $261.61M | $292.58M | - | $30.97M | 11.84% | -0.494% |
| ABBV AbbVie Inc. | 148,913 | $37.47M | $37.15M | - | -$326,119.16 | -0.87% | -0.546% |
| AMAT Applied Materials, Inc. | 65,201 | $22.29M | $33.06M | - | $10.78M | 48.37% | -5.132% |
| AMD Advanced Micro Devices, Inc. | 298,410 | $61.15M | $153.49M | - | $92.34M | 150.99% | +6.493% |
| AMZN Amazon.com Inc | 1.27M | $265.64M | $334.02M | - | $68.38M | 25.74% | -0.932% |
| AZN AstraZeneca PLC American Depositary Shares | 184,279 | $34.94M | $28.83M | - | -$6.11M | -17.49% | -0.496% |
| BFLY Butterfly Network, Inc. | 14.34M | $110.37M | $126.72M | - | $16.36M | 14.82% | -0.226% |
| BKR Baker Hughes Company | 493,519 | $29.08M | $31.98M | - | $2.91M | 10.01% | +2.16% |
| BLCO Bausch + Lomb Corporation | 1.92M | $26.88M | $32.7M | - | $5.83M | 21.69% | +0.412% |
| BRKR Bruker Corporation | 252,169 | $15.18M | $14.55M | - | -$625,378.69 | -4.12% | -0.397% |
| BSX Boston Scientific Corporation | 113,096 | $4.83M | $5.86M | - | $1.03M | 21.44% | +0.271% |
| CAH Cardinal Health Inc. | 18,018 | $4.28M | $4.24M | - | -$42,702.58 | -1% | +1.708% |
| CI The Cigna Group | 412,223 | $114.04M | $116.48M | - | $2.43M | 2.13% | +1.644% |
| CNC Centene Corporation | 1.89M | $66.19M | $127.27M | - | $61.08M | 92.27% | +2.18% |
| CSCO Cisco Systems, Inc. | 413,332 | $35M | $46.17M | - | $11.16M | 31.89% | -1.569% |
| CVS CVS Health Corporation | 4.82M | $295.59M | $468.83M | - | $173.24M | 58.61% | +2.295% |
| DHR Danaher Corporation | 1.15M | $219.5M | $232M | - | $12.5M | 5.7% | -0.706% |
| DKS Dick's Sporting Goods, Inc. | 401,067 | $83.8M | $81M | - | -$2.79M | -3.33% | -0.143% |
| DOCN DigitalOcean Holdings Inc. | 84,812 | $4.08M | $11.02M | - | $6.94M | 170.01% | -1.784% |
| ELV Elevance Health, Inc. | 66,599 | $25.76M | $26.66M | - | $904,414.69 | 3.51% | +0.525% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Larry Robbins?
The largest contributions to the portfolio's profits come from the following stocks: VMED - $1.53B, Tenet Healthcare Corporation - $1.29B, HCA Healthcare Inc - $1.25B, Thermo Fisher Scientific Inc - $1.15B, and McKesson Corporation - $1.03B. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Dxc Technology Co - $417.5M, Brookdale Senior Living Inc - $387.92M, Hertz Global Holdings, Inc - $319.93M, Paramount Global - $280.5M, and PVH Corp - $233.37M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Larry Robbins's portfolio generate?
The portfolio generates substantial dividend income, with a total of $1.6B earned over time. The largest contributors to dividend income include VEREIT Inc - $150.68M, Chimera Investment Corporation - $98.74M, CVS Health Corporation - $85.83M, HCA Healthcare Inc - $81.54M, and RR Donnelley & Sons Co - $66.95M. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Larry Robbins's monthly returns?
Larry Robbins's monthly returns appear quite volatile. The gap between stronger and weaker months is meaningful, which suggests that the strategy can experience noticeable swings over relatively short periods. For users assessing this profile, that usually means returns may be attractive over time, but the path can be uneven and harder to tolerate during weaker periods.
Can Larry Robbins's strategy be considered aggressive or moderate?
Larry Robbins's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow Larry Robbins's strategy?
Larry Robbins's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
